Somatic gene therapy for dyslipidemias

Journal of Laboratory and Clinical Medicine

Volumn 134, Issue 3, 1999, Pages 194-214

  Belalcazar, Maria ^b   Chan, Lawrence ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DYSLIPIDEMIA; GENE THERAPY; GENE TRANSFER; LIPID METABOLISM; TRANSFER VECTOR;

EID: 0033198804     PISSN: 00222143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-2143(99)90199-3     Document Type: Article

References (191)

1. 1. Division of Vital Statistics, National Center for Health Statistics, CDC. Preliminary data on births and deaths-United States, 1995. In: CDC's Morbidity and Mortality Weekly Report; October 25, 1996. Volume 45, No. 42. ASCII text edition converted to HTML (http://www.cdc.gov.cgi-bin).
2. 2. Kochanek KD, Hudson BL. Advance report of final mortality statistics, 1992. Final data from the Centers for Disease Control and Prevention/National Center for Health Statistics. Monthly Vital Statistics Report 1995;43:1-13.
3. 3. Schiel R, Bambauer R, Muller U. Low-density lipoprotein apheresis versus lipid lowering drugs in the treatment of severe hypercholesterolemia: four years' experience. Artif Organs 1996;20:318-23.
4. 4. Seidel D. H.E.L.P. Apheresis therapy in the treatment of severe hypercholesterolemia: 10 years of clinical experience. Artif Organs 1996;20:303-10.
5. 5. Lea A, McTavish D. Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias. Drugs 1997;53:828-47.
6. 6. Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The Metabolic and molecular bases of inherited disease (vol II). New York: McGraw-Hill; 1995. p. 1981-2030.
7. 7. Leitersdorf E, Eisenberg S, Eliav O, Friedlander Y, Berkman N, Dann EJ, et al. Genetic determinants of responsiveness in the HMG-CoA reductase inhibitor fluvastatin in patients with molecularly defined heterozygous familial hypercholesterolemia. Circulation 1993;87:S35-44.
8. 8. Kannel WB. Range of serum cholesterol values in the population developing coronary artery disease. Am J Cardiol 1995;76:69C-77C.
9. 9. Pekkanen J, Linn S, Heiss G, Suchindran CM, Leon A, Rifkind BM, et al. Ten year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med 1990;322:1700-7.
10. 10. Belalcazar LM, Ballantyne CM. Defining specific goals of therapy in treating dyslipidemia in the patient with low high-density lipoprotein cholesterol. Prog Cardiovasc Dis 1998;41:151-74.
11. 11. Anderson WF, Brenner MK, Miller AD, Wilson JM, Bordignon C, Heard JM, et al, editors. Human gene marker/therapy clinical protocols. Hum Gene Ther 1997;8:2301-34.
12. 12. Wilson JM, Grossman M, Raper SE, Baker JR, Newton RS, Thoene JG. Clinical protocol. Ex vivo gene therapy of familial hypercholesterolemia. Hum Gene Ther 1992;3:179-222.
13. 13. Grossman M, Rader DJ, Muller DWM, Kolansky DM, Kozarsky K, Clark BJ, et al. A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia. Nat Med 1995;1:1148-54.
14. 14. Wolff JA, Malone RW, Williams P, Chong W, Ascadi G, Jani A, et al. Direct gene transfer into mouse muscle in vivo. Science 1990;247:1465-8.
15. 15. Tripathy SK, Svensson EC, Black HB, Gold-Wasser E, Margalith M, Hobart PM, et al. Long-term expression of erythropoietin in the systemic circulation of mice after intramuscular injection of plasmid DNA vector. Proc Natl Acad Sci USA 1996;93:10876-80.
16. 16. Nitta Y, Tashiro F, Tokui M, Shimada A, Takei I, Tabayashi K, et al. Systemic delivery of interleukin 10 by intramuscular injection of expression plasmid DNA prevents autoimmune diabetes in nonobese diabetic mice. Hum Gene Ther 1998;9:1701-7.
17. 17. Wolff JA, Ludtke JJ, Acsadi G, Williams P, Jani A. Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle. Hum Mol Genet 1992;1:363-9.
18. 18. Buttrick PM, Kass A, Kitsis RN, Kaplan ML, Leinwand LA. Behavior of genes directly injected into the rat heart in vivo. Circ Res 1992;70:193-8.
19. 19. Isner JM, Pieczek A, Schainfeld R, et al. Early report: clinical evidence of angiogenesis following arterial gene transfer of phVEGF165. Lancet 1996;348:370-4.
20. 20. Kass-Eisler A, Li K, Leinwand LA. Prospects for gene therapy with direct injection of polynucleotides. Ann NY Acad Sci 1995;772:232-40.
21. 21. Isner JM. Angiogenesis for revascularization of ischaemic tissues. Eur Heart J 1997;18:1-2.
22. 22. Baumgartner I, Pieczek A, Manor O, Blair R, Kearney M, Walsh K, et al. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 1998;97:1114-23.
23. 23. Vale PR, Losordo DW, Symes JF, Isner JM. Gene therapy for myocardial angiogenesis. Circulation 1998;98:I-322.
24. 24. Wu GY, Wilson JM, Shalaby F, Grossman M, Shafritz DA, Wu CH. Receptor-mediated gene delivery in vivo. Partial correction of genetic analbuminemia in Nagase rats. J Biol Chem 1991;266:14338-42.
25. 25. Kaneda A, Iwai K, Uchida T. Increased expression of DNA cointroduced with nuclear protein in adult rat liver. Science 1989;243:375-8.
26. 26. Alino SF, Crespo J, Bobadilla M, Lejarreta M, Blaya C, Crespo A. Expression of human α1-antitrypsin in mouse after in vivo gene transfer to hepatocytes by small liposomes. Biochem Biophys Res Commun 1994;204:1023-30.
27. 27. Hara T, Aramaki Y, Takada S, Koike K, Tsuchiya S. Receptor-mediated transfer of pSV2CAT DNA to mouse liver cells using asialofetuin-labeled liposomes. Gene Ther 1995;2:784-8.
28. 28. Singhal A, Huang L. Gene transfer in mammalian cells using liposomes as carriers. In: Jon A. Wolff, editor. Gene therapeutics. Methods and applications of direct gene transfer. Boston: Birkhauser; 1994. p. 118-42.
29. 29. Eck SL, Wilson JM. Gene-based therapy. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Goodman A, editors. Goodman and Gilman's the pharmacological basis of therapeutics. New York: McGraw-Hill; 1996. p. 77-101.
30. 30. Truong-Le VL, August JT, Leong KW. Controlled gene delivery by DNA-gelatin nanospheres. Hum Gene Ther 1998;9:1709-17.
31. 31. Rensen PCN, vanDijk MCM, Havenaar EC, Bijsterbosch MK, Kruijt JK, van Berkel TJC. Selective liver targeting of antivirals by recombinant chylomicrons: a new therapeutic approach to hepatitis B. Nat Med 1995;1:221-5.
32. 32. Hara T, Tan Y, Huang L. In vivo gene delivery to the liver using reconstituted chylomicron remnants as a novel non-viral vector. Proc Natl Acad Sci USA 1997;94:14547-52.
33. 33. O'Malley BW Jr, Ledley FD. Somatic gene therapy. Methods for the present and future. Arch Otolaryngol Head Neck Surg 1993;119:1100-7.
34. 34. Kohn DB, Conrad C. Gene therapy and viruses. In: Richman DD, Whitley RJ, Hayden FG, editors. Clinical virology. New York: Churchill Livingstone; 1997. p. 323-41.
35. 35. Ali M, Lemoine NR, Ring CJA. The use of DNA viruses as vectors for gene therapy. Gene Ther 1994;1:367-84.
36. 36. Ferry N, Heard JM. Liver-directed gene transfer vectors. Hum Gene Ther 1998;9:1975-81.
37. 37. Verma IM, Somia N. Gene therapy: promises, problems and prospects. Nature 1997;389:239-43.
38. 38. Sandig V, Strauss M. Liver-directed gene transfer and application to therapy. J Mol Med 1996;74:205-12.
39. 39. Linden RM, Woo SLC. Avant-garde gene therapy. Nat Med 1999;5:21-2.
40. 40. Ferry N, Duplessis O, Houssin D, Danos O, Heard JM. Retroviral-mediated gene transfer into hepatocytes in vivo. Proc Natl Acad Sci USA 1991;88:8377-81.
41. 41. Bowling WM, Kennedy SC, Cai SR, Duncan JR, Gao CH, Flye MW, et al. Portal branch occlusion safely facilitates in vivo retroviral vector transduction of rat liver. Hum Gene Ther 1996;7:2113-21.
42. 42. Bosch A, McCray PB Jr, Walters KS, Bodner M, Jolly DJ, Van Es HHG, et al. Effects of keratinocyte and hepatocyte growth factor in vivo: implications for retrovirus-mediated gene transfer to liver. Hum Gene Ther 1998;9:1747-54.
43. 43. Patijn GA, Lieber A, Meuse L, Winther B, Kay MA. High efficiency retrovirus-mediated gene transfer into the livers of mice. Hum Gene Ther 1998;9:1449-56.
44. 44. Bartz SR, Vodicka MA. Production of high-titer human immunodeficiency virus type 1 pseudotyped with vesicular stomatitis virus glycoprotein. Methods 1997;4:337-42.
45. 45. Salmons B, Saller RM, Baumann JG, Gunzburg WH. Construction of retroviral vectors for targeted delivery and expression of therapeutic genes. Leukemia 1995;(suppl 1):S53-S60.
46. 46. Kafri T, Blomer U, Peterson DA, Gage FH, Verma IM. Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors. Nat Genet 1997;17: 314-7.
47. 47. Fisher KJ, Jooss K, Alston J, Yang Y, Haecker SE, High K, et al. Recombinant adeno-associated virus for muscle directed gene therapy. Nat Med 1997;3:306-12.
48. 48. Xiao X, Li J, Samulski RJ. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virol 1996;8098-108.
49. 49. Jooss K, Yang Y, Fisher KJ, Wilson JM. Transduction of dendtritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers. J Virol 1998;72:4212-23.
50. 50. Xiao W, Berta SC, Lu MM, Moscioni AD, Tazelaar J, Wilson JM. Adeno-associated virus as a vector for liver-directed gene therapy. J Virol 1998;72:10222-6.
51. 51. Snyder RO, Miao C, Meuse L, Tubb J, Donahue BA. Lin HF, et al. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors. Nat Med 1999;5:64-70.
52. 52. Herzog RW, Yang EY, Couto LB, Hagstrom JN, Elwell D, Fields PA, et al. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat Med 1999;5: 56-63.
53. 53. Ye X, Rivera VM, Zoltick P, Cerasoli F, Schnell MA, Gao G, et al. Regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer. Science 1999;283:88-91.
54. 54. Inoue N, Russell DW. Packaging cells based on inducible gene amplification for the production of adeno-associated virus vectors. J Virol 1998;72:7024-31.
55. 55. Grimm D, Kern A, Rittner K, Kleinschmidt JA. Novel tools for production and purification of recombinant adenoassociated virus vectors. Hum Gene Ther 1999;9: 2745-60.
56. 56. Gao G, Qu G, Faust LZ, Engdahl RK, Xiao W, Hughes JV, et al. High-titer adeno-associated viral vectors from a Rep/Cap cell line and hybrid shuttle virus. Hum Gene Ther 1998;9:2353-62.
57. 57. Gerard RD, Chan L. Adenovirus-mediated gene transfer: strategies and applications in lipoprotein research. Curr Opin Lipidol 1996;7:105-11.
58. 58. Leiden JM. Adenovirus-mediated gene transfer as an in vivo probe of lipoprotein metabolism. Circulation 1996;94: 2046-51.
59. 59. Herz J, Gerard RD. Adenovirus-mediated transfer of low density lipoprotein receptor gene acutely accelerates cholesterol clearance in normal mice. Proc Natl Acad Sci USA 1993;90:2812-6.
60. 60. Chan L. Use of somatic gene transfer to study lipoprotein metabolism in experimental animals in vivo. Curr Opin Lipidol 1995;6:335-40.
61. 61. Wang Y, Krushel LA, Edelman GM. Targeted DNA recombination in vivo using an adenovirus carrying the Cre recombinase gene. Proc Natl Acad Sci USA 1996;93: 3932-6.
62. 62. Breslow JL. Transgenic mouse models of lipoprotein metabolism and atherosclerosis. Proc Natl Acad Sci USA 1993;90:8314-8.
63. 63. Maeda N. Gene targeting in mice as a strategy for understanding lipid metabolism and atherogenesis. Curr Opin Lipidol 1993;4:90-4.
64. 64. Kass-Eisler A, Falck-Pedersen E, Elfenbein DH, Alvira M, Buttrick PM, Leinwand LA. The impact of developmental stage, route of administration and the immune system on adenovirus-mediated gene transfer. Gene Ther 1994;1:395-402.
65. 65. Yang Y, Nunes FA, Berencsi K, Furth EE, Gonczol E, Wilson JM. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 1994;91:4407-11.
66. 66. Kafri T, Morgan D, Krahl T, Sarvetnick N, Sherman L, Verma I. Cellular and immune response to adenoviral vector infected cells does not require de novo viral gene expression: implications for gene therapy. Proc Natl Acad Sci USA 1998;95:11377-82.
67. 67. Yang Y, HCJ Ertl, Wilson JM. MHC class 1-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. Immunity 1994;1:433-42.
68. 68. Yang Y, Li Q, Ertl HCJ, Wilson JM. Cellular and humoral responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol 1995;69:2004-15.
69. 69. Jiao S, Cole TG, Kitchens RT, Pfleger B, Schonfeld G. Genetic heterogeneity of lipoproteins in inbred strains of mice: analysis by gel permeation chromatography. Metabolism 1990;39:155-60.
70. 70. Rubin EM, Ishida BY, Clift SM, Krauss RM. Expression of human apolipoprotein A-I in transgenic mice results in reduced plasma levels of murine apolipoprotein A-I and the appearance of two new high density lipoprotein size subclasses. Proc Natl Acad Sci 1991;88:434-8.
71. 71. Fruchart JC, Ailhaud G, Bard JM. Heterogeneity of high density lipoprotein particles. Circulation 1993;87(suppl):III22-7.
72. 72. Plump AS, Smith JD, Hayek T, Aalto-Setala K, Walsh A, Verstuyft JG, et al. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 1992;71: 343-53.
73. 73. Zhang SH, Reddick RL, Piedrahita JA, Maeda N. Spontaneous hyperhcolesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 1992;258:468-71.
74. 74. Mahley RW, Rall SC. Type III hyperlipoproteinemia (dysbetalipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular bases of inherited disease (vol II). New York: McGraw-Hill; 1995. p. 1953-80.
75. 75. Chan L. Apolipoprotein B, the major protein component of triglyceride-rich and low density lipoproteins. J Biol Chem 1992;267:25621-4.
76. 76. Teng B, Blumenthal S, Forte T, Navaratnam N, Scott J, Gotto AM, et al. Adenovirus-mediated gene transfer of rat apolipoprotein B mRNA-editing protein in mice virtually eliminates apolipoprotein B-100 and normal low density lipoprotein production. J Biol Chem 1994;269:29395-404.
77. 77. Van't Hooft FM, Hardman DA, Kane JP, Havel RJ. Apolipoprotein B (B-48) of rat chylomicrons is not a precursor of the apolipoprotein of low density lipoproteins. Proc Natl Acad Sci USA 1982;79:179-82.
78. 78. Breckenridge WC, Roberts A, Kuksis A. Lipoprotein levels in genetically selected mice with increased susceptibility to atherosclerosis. Arteriosclerosis 1985;5:256-64.
79. 79. Schultz JR, Rubin EM. The properties of HDL in genetically engineered mice. Curr Opin Lipidol 1994;5:126-37.
80. 80. Aubert R, Perdereau D, Roubiscoul D, et al. Genetic variations in serum lipid levels of inbred mice and response to hypercholesterolemic diet. Lipids 1988;23:48-54.
81. 81. Paigen B, Holmes PA, Mitchell D, Albee D. Comparison of atherosclerotic lesions and HDL-lipid levels in male, female, and testosterone-treated female mice from strains C57BL/6, BALB/c,and C3H. Atherosclerosis 1987;64: 215-21.
82. 82. Ishibashi S, Brown MS, Goldstein JL, Gerard RD, Hammer RE, Herz J. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest 1993;92: 883-93.
83. 83. Ishibashi S, Goldstein JL, Brown MS, Herz J, Burns DK. Massive xanthomatosis and atherosclerosis in cholesterol-fed low density lipoprotein receptor-negative mice. J Clin Invest 1994;93:1885-93.
84. 84. Acton S, Rigotti A, Landschulz KT, et al. Identification of scavenger receptor SR-B1 as a high density lipoprotein receptor. Science 1996;271:518-20.
85. 85. Kozarsky KF, Donahee MH, Rigotti A, Iqbal SN, Edelman ER, Krieger M. Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol levels. Nature 1997;387:414-7.
86. 86. Arai T, Wang N, Bezouevski M, Welch C, Tall AR. Decreased atherosclerosis in heterozygous low density lipoprotein receptor-deficient mice expressing the scavenger receptor BI transgene. J Biol Chem 1999;274:2366-71.
87. 87. Brown M, Hesler C, Tall AR. Plasma enzymes and transfer proteins in cholesterol metabolism. Curr Opin Lipidol 1990;1:122-7.
88. 88. Foger B, Santamarina-Fojo S, Shamburek RD, Parrot CL, Talley GD, Brewer HB Jr. Plasma phospholipid transfer protein. Adenovirus-mediated overexpression in mice leads to decreased plasma high density lipoprotein (HDL) and enhanced hepatic uptake of phospholipids and cholesteryl esters from HDL. J Biol Chem 1997;272:27393-400.
89. 89. Ehnholm S, van Dijk KW, van't Hof B, van der Zee A, Olkkonen VM, Jauhiainen M, et al. Adenovirus mediated overexpression of human phospholipid transfer protein alters plasma HDL levels in mice. J Lipid Res 1998;39: 1248-53.
90. 90. Barrans A, Jaspard B, Barbaras R, Chap H, Perret B, Collet X. Pre-B HDL: structure and metabolism. Biochim Biophys Acta 1996;1300:73-85.
91. 91. Jiang X, Francone OL, Bruce C, Ross M, Mar J, et al. Increased preB-high density lipoprotein, apolipoprotein AI, and phospholipid in mice expressing the human phospholipid transfer protein and human apolipoprotein AI transgenes. J Clin Invest 1996;98:2373-80.
92. 92. Jiang X, Bruce C, Mar J, Lin M, Ji Y, Francone OL, et al. Targeted mutation of plasma phospholipid transfer protein gene markedly reduces high density lipoprotein levels. J Clin Invest 1999;103:907-14.
93. 93. Dugi KA, Vaisman BL, Sakai N, Knapper CL, Meyn SM. Brewer HB, et al. Adenovirus-mediated expression of hepatic lipase in LCAT transgenic mice. J Lipid Res 1997;38:1822-32.
94. 94. Berard AM, Remaley AT, Vaisman BL, Paigen B, Hoyt RF Jr, Meyn SM, et al. High plasma HDL concentrations associated with enhanced atherosclerosis in transgenic mice overexpressing lecithin cholesterol acyltransferase. Nat Med 1997;3:744-9.
95. 95. Simard G, Perret B, Durand S, Collet X, Chap H, Douste-Blazy L. Phosphatidylcholine and triacylglycerol hydrolysis in HDL as induced by hepatic lipase: modulation of the phospholipase activity by changes in the particle surface or in the lipid core. Biochim Biophys Acta 1989;1001:225-33.
96. 96. Azema C, Marques-Vidal P, Lespine A, Simard G, Chap H, Perret B. Kinetic evidence for phosphatidylethanolamine and triacylglycerol as preferential substrates for hepatic lipase in HDL subfractions: modulation by changes in the particle surface, or in the lipid core. Biochim Biophys Acta 1990;1046:73-80.
97. 97. Dugi KA, Knapper CL, Applebaum-Bowden D, Bensadoun A, Meyn SM, Le TT, et al. In vivo evidence for a non-lipolytic role of hepatic lipase in the metabolism of high density lipoprotein [abstract]. Circulation 1996;94:1-398.
98. 98. Komaromy M, Azhar S, Cooper AD. Chinese hamster ovary cells expressing a cell surface-anchored form of hepatic lipase. J Biol Chem 1996;271:16906-14.
99. 99. Hoeg JM, Santamarina-Fojo S, Berard AM, Cornhill JF, Herderick EE, et al. Overexpression of lecithin:cholesterol acyltransferase in transgenic rabbits prevents diet-induced atherosclerosis. Proc Natl Acad Sci USA 1996;93:11448-53.
100. 100. Rubinsztein DC, Cohen JC, Berger GM, van der Westhuyzen DR, Coetzee GA, Gevers W. Chylomicron remnant clearance from plasma is normal in familial hypercholesterolemic homozygotes with defined receptor defects. J Clin Invest 1990;86:1306-12.
101. 101. Willnow TE, Sheng Z, Ishibashi S, Herz J. Inhibition of hepatic chylomicron remnant uptake by gene transfer of a receptor antagonist. Science 1994;264:1471-4.
102. 102. Rohlmann A, Gotthardt M, Hammer RE, Herz J. Inducible inactivation of hepatic LRP gene by Cre-mediated recombination confirms role of LRP in clearance of chylomicron remnants. J Clin Invest 1998;101:689-95.
103. 103. Havel RJ, Fielding CJ, Olivecrona T, Shore VG, Fielding PE, Egelrud T. Cofactor activity of protein components of human very low density lipoproteins in the hydrolysis of triglycerides by lipoprotein lipase from different sources. Biochemistry 1973;12:1828-33.
104. 104. Windler E, Havel RJ. Inhibitory effects of C apolipoproteins from rats and humans on the uptake of triglyceriderich lipoproteins and their remnants by the perfused rat liver. J Lipid Res 1985;26:556-65.
105. 105. Jong MC, Dahlmans VE, van Gorp PJ, van Dijk KW, Breuer ML, Hofker MH, et al. In the absence of the low density lipoprotein receptor, human apolipoprotein C1 overexpression in transgenic mice inhibits the hepatic uptake of very low density lipoproteins via a receptor-associated protein-sensitive pathway. J Clin Invest 1996;98: 2259-67.
106. 106. Oka K, Kobayashi K, Sullivan M, Martinez J, Teng B, Ishimura-Oka K, et al. Tissue-specific inhibition of apolipoprotein B mRNA editing in the liver by adenovirus mediated transfer of a dominant negative mutant APOBEC-I leads to increased low density lipoprotein in mice. J Biol Chem 1997;272:1456-60.
107. 107. Teng B, Ishida B, Forte TM, Blumenthal S, Song LZ, Gotto AM, et al. Effective lowering of plasma, LDL, and esterified cholesterol in LDL receptor-knockout mice by adenovirus-mediated gene delivery of apoB mRNA editing enzyme (ApobecI). Arterioscler Thromb Vasc Biol 1997;17:889-97.
108. 108. Kozarsky KF, Bonen DK, Giannoni F, Funahashi T, Wilson JM, Davidson NO. Hepatic expression of the catalytic subunit of the apolipoprotein B mRNA editing enzyme (apobec-I) ameliorates hypercholesterolemia in LDL receptor deficient rabbits. Hum Gene Ther 1996;7:943-57.
109. 109. Schwarz M, Lund EG, Russell DW. Two 7α-hydroxylase enzymes in bile acid biosynthesis. Curr Opin Lipidol 1998;9:113-8.
110. 110. Spady DK, Cuthbert JA, Willard MN, Meidell RS. Feedback regulation of hepatic 7α-hydroxylase expression by bile salts in the hamster. J Biol Chem 1996;271:18623-31.
111. 111. Schwarz M, Lund EG, Setchell KDR, Kayden HJ, Zerwekh JE, Bjorkhem I, et al. Disruption of cholesterol 7α-hydroxylase gene in mice. J Biol Chem 1996;271: 18024-31.
112. 112. Schwarz M, Lund EG, Lathe R, Bjorkhem I, Russell DW. Identification and characterization of a mouse oxysterol 7α-hydroxylase cDNA. J Biol Chem 1997;272:23995-4001.
113. 113. Faustinella F, Smith LC, Chan L. Functional topology of a surface loop shielding the catalytic center in lipoprotein lipase. Biochemistry 1992;31:7219-23.
114. 114. Kobayashi J, Applebaum-Bowden D, Dugi KA, Brown DR, Kashyap VS, Parrot C, et al. Analysis of protein structure-function in vivo. Adenovirus mediated transfer of lipase lid mutants in hepatic lipase-deficient mice. J Biol Chem 1996;271:26296-301.
115. 115. Hide WA, Chan L, Li WH. Structure and evolution of the lipase superfamily. J Lipid Res 1992;33:167-78.
116. 116. Datta S, Luo CC, Li WH, vanTuinen P, Ledbetter DH, Brown MA, et al. Human hepatic lipase. J Biol Chem 1988;263:1107-10.
117. 117. Dugi KA, Dichek HL, Santamarina-Fojo. Human hepatic lipase: the loop covering the catalytic site mediates lipase substrate specificity. J Biol Chem 1995;270:25396-401.
118. 118. Utermann G. The mysteries of lipoprotein (a). Science 1989;246:904-10.
119. 119. Scanu AM, Lawn RM, Berg K. Lipoprotein (a) and atherosclerosis. Ann Intern Med 1991;115:209-18.
120. 120. McLean JW, Tomlinson JE, Kuang WJ, Eaton DL, Chen EY, Fless GM, et al. cDNA sequence of human apolipoprotein (a) is homologous to plasminogen. Nature 1987;300:132-7.
121. 121. Scanu AM, Pfaffinger D, Lee JC, Hinman J. A single point mutation (Trp72-→Arg) in human apo(a) kringle 4-37 associated with a lysine binding defect in Lp(a). Biochim Biophys Acta 1994;1227:41-5.
122. 122. Harpel PC, Gordon BR, Parker TS. Plasmin catalyzes binding of lipoprotein (a) to immobilized fibrinogin and fibrin. Proc Natl Acad Sci USA 1989;86:3847-51.
123. 123. Hughes SD, Lou XJ, Ighani S, Verstuyft J, Grainger DJ, Lawn RM, et al. Lipoprotein (a) vascular accumulation in mice. In vivo analysis of the role of lysine binding sites using recombinant adenovirus. J Clin Invest 1997;100:1493-500.
124. 124. Boonmark NW, Lou XJ, Yang ZJ, Schwartz K, Zhang JL, Rubin EM, et al. Modification of apolipoprotein(a) lysine binding site reduces atherosclerosis in transgenic mice. J Clin Invest 1997;100:558-64.
125. 125. Weisgraber KH, Rall SC Jr, Mahley RW. Human E apoprotein heterogeneity. Cysteine-arginine interchanges in the amino acid sequence of the apo-E isoforms. J Biol Chem 1981;256:9077-83.
126. 126. Rall SC Jr, Weisgraber KH, Mahley RW. Human apolipoprotein E. The complete amino acid sequence. J Biol Chem 1982;257:4171-8.
127. 127. Tsukamoto K, Smith P, Glick JM, Rader DJ. Liver-directed gene transfer and prolonged expression of three major human apoE isoforms in apoE deficient mice. J Clin Invest 1997;100:107-14.
128. 128. Kozarsky KF, McKinley DR, Austin LL, Raper SE, Stratford-Perricaudet LD, Wilson JM. In-vivo correction of low density lipoprotein receptor deficiency in the Watanabe heritable hyperlipidemic rabbit with recombinant adenoviruses. J Biol Chem 1994;289:13695-702.
129. 129. Li J, Fang B, Eisensmith RC, Li XHC, Nasonkin I, Lin-Lee Y-C, et al. In-vivo gene therapy for hyperlipidemia: phenotypic correction in Watanabe rabbits by hepatic delivery of the rabbit LDL receptor gene. J Clin Invest 1995;95:768-73.
130. 130. Raper SE, Grossman M, Rader DJ, Thoene JG, Clark BJ III, Kolansky DM, et al. Safety and feasibility of liver-directed ex vivo gene therapy for homozygous familial hypercholesterolemia. Ann Surg 1996;223:116-26.
131. 131. Hughes SD, Rouy D, Navaratnam N, Scott J, Rubin EM. Gene transfer of cytidine deaminase apobec-I lowers lipoprotein(a) in transgenic mice and induces apolipoprotein editing in rabbits. Hum Gene Ther 1996;7:39-49.
132. 132. Yamanaka S, Balestra M, Ferrell L, Fan J, Arnold D, Taylor S, et al. Apolipoprotein B mRNA-editing protein induces hepatocellular carcinoma and dysplasia in transgenic animals. Proc Natl Acad Sci USA 1995;92:8483-7.
133. 133. Yamamoto T, Davis CG, Brown MS, Schneider WJ, Casey ML, Goldstein JL, et al. The human LDL receptor: a cysteine-rich protein with multiple Alu sequences in its mRNA. Cell 1984;39:27-38.
134. 134. Takahashi S, Kawarabayashi Y, Nakai T, Sakai J, Yamamoto T. Rabbit very low density lipoprotein receptor: a low density lipoprotein receptor-like protein with a distinct ligand specificity. Proc Natl Acad Sci 1992;89:9252-6.
135. 135. Oka K, Ishimura-Oka K, Chu MJ, Sullivan M, Krushkal J, Li WH, et al. Mouse very-low-density-lipoprotein receptor (VLDLR) cDNA cloning, tissue-specific expression and evolutionary relationship with the low-density-lipoprotein receptor. Eur J Biochem 1994;224:975-82.
136. 136. Yamamoto T, Takahashi S, Sakai J, Kawarabayasi Y. The very low density lipoprotein receptor, a second lipoprotein receptor that may mediate uptake of fatty acids into muscle and fat cells. Trends Cardiovasc Med 1993;3:144-8.
137. 137. Takahashi S, Suzuki J, Kohono M, Oida K, Tamai T, Miyabo S, et al. Enhancement of the binding of triglyceride-rich lipoproteins to the very low density lipoprotein receptor by apolipoprotein E and lipoprotein lipase. J Biol Chem 1995;270:15747-54.
138. 138. Frykman P, Brown M, Yamamoto T, Goldstein J, Herz J. Normal plasma lipoproteins and fertility in gene-targeted mice homozygous for a disruption in the gene coding very low density lipoprotein receptor. Proc Natl Acad Sci USA 1995;92:8453-7.
139. 139. Kobayashi K, Oka K, Forte T, Ishida B, Teng B, Ishimura-Oka K, et al. Reversal of hypercholesterolemia in low density lipoprotein receptor knockout mice by adenovirus-mediated gene transfer of the very low density lipoprotein receptor. J Biol Chem 1996;271:6852-60.
140. 140. Kozarsky KF, Jooss K, Doanhee M, Strauss III JF, Wilson JM. Effective treatment of familial hypercholesterolaemia in the mouse model using adenovirus-mediated transfer of the VLDL receptor gene. Nat Genet 1996;13:54-62.
141. 141. Chowdhury JR, Grossman M, Gupta S, Chuwdhury NR, Baker JR, Wilson JM. Long-term improvement of hypercholesterolemia after ex vivo gene therapy in LDLR deficient rabbits. Science 1991;254:1802-5.
142. 142. van Dijk KW, van Vlijmen BJM, van der Zee A, van't Hof Belinda, van der Boom H, Kobayashi K, et al. Reversal of hypercholesterolemia in apolipoprotein E2 and apolipoprotein E3-Leiden transgenic mice by adenovirus-mediated gene transfer of the VLDL receptor. Arterioscler Thromb Vasc Biol 1998;18:7-12.
143. 143. Semenkovich CF, Chen SH, Wims M, Luo CC, Li WH, Chan L. Lipoprotein lipase and hepatic lipase mRNA tissue specific expression, developmental regulation, and evolution. J Lipid Res 1989;30:423-31.
144. 144. Zechner R. The tissue-specific expression of lipoprotein lipase: implications for energy and lipoprotein metabolism. Curr Opin Lipidol 1997;8:77-88.
145. 145. Zsigmond E, Kobayashi K, Tzung KW, Li L, Fuke Y, Chan L. Adenovirus-mediated gene transfer of human lipoprotein lipase ameliorates the hyperlipidemias associated with apolipoprotein E and LDL receptor deficiencies in mice. Hum Gene Ther 1997;8:1921-33.
146. 146. Ashbourne Excoffon KJD, Liu G, Miao L, Wilson JE, McManus BM, Semenkovich CF, et al. Correction of hypertriglyceridemia and impaired fat tolerance in lipoprotein lipase-deficient mice by adenovirus-mediated expression of human lipoprotein lipase. Arterioscler Thromb Vasc Biol 1997;17:2532-9.
147. 147. Benlian P, De Gennes JL, Foubert L, Zhang H, Gagne SE, Hayden MR. Premature atherosclerosis in patients with familial chylomicronemia caused by mutations in the lipoprotein lipase gene. N Engl J Med 1996;335:848-54.
148. 148. Bijvoet S, Gagne E, Moorjani S, Gagne C, Henderson HE, Fruchart JC, et al. Alterations in plasma lipoproteins and apolipoproteins before the age of 40 in heterozygous for lipoprotein lipase deficiency. J Lipid Res 1996;37:640-50.
149. 149. Yla-Herttuala S, Lipton BA, Rosenfeld ME, Goldberg IJ, Steinberg D, Witztum JL. Macrophages and smooth muscle cells express lipoprotein lipase in human and rabbit atherosclerotic lesions. Proc Natl Acad Sci USA 1991;88:10143-7.
150. 150. Renier G, Skamene E, DeSanctis JB, Radzioch D. High macrophage lipoprotein lipase expression and secretion are associated in inbred murine strains with susceptibility to atherosclerosis. Arterioscl Thromb 1993;13:190-6.
151. 151. Semenkovich CF, Coleman T, Daugherty A. Effects of heterozygous lipoprotein lipase deficiency on diet-induced atherosclerosis in mice. J Lipid Res 1998;39:1141-51.
152. 152. Stevenson SC, Marshall-Neff J, Teng B, Lee CB, Roy S, McClelland A. Phenotypic correction of hypercholesterolemia in apoE-deficient mice by adenovirus-mediated in vivo gene transfer. Arterioscler Thromb Vasc Biol 1995;15:479-84.
153. 153. Kashyap VS, Santamarina-Fojo S, Brown DR, Parrott CL, Applebaum-Bowden D, Meyn S, et al. Apolipoprotein E deficiency in mice: gene replacement and prevention of atherosclerosis using adenovirus vectors. J Clin Invest 1995;96:1612-20.
154. 154. Sullivan PM, Mezdour H, Aratani Y, Knouff C, Najib J, Reddick RL, et al. Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis. J Biol Chem 1997;272:17972-80.
155. 155. Huang Y, Liu XQ, Rall SC, Taylor JM, von Eckardstein A, Assmann G, et al. Overexpression and accumulation of apolipoprotein E as a cause of hypertriglyceridemia. J Biol Chem 1998;273:26388-93.
156. 156. vanDijk KW, van Vlijmen BJM, van't Hof HB, van der Zee A, Santamarina-Fojo S, van Berkel TJC, et al. In LDL receptor-deficient mice, catabolism of remnant lipoproteins requires a high level of apoE but is inhibited by excess apoE. J Lipid Res 1999;40:336-44.
157. 157. Gordon DJ, Probstfield JL, Garrisson RJ, Neaton JD, Castelli WP, Knoke JD, et al. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation 1989;79:8-15.
158. 158. Miller NE. Associations of high-density lipoprotein subclasses and apo-lipoproteins with ischemic heart disease and coronary atherosclerosis. Am Heart J 1987;113:589-97.
159. 159. Walsh A, Ito Y, Breslow JL. High levels of human apolipoprotein A-I in transgenic mice result in increased plasma levels of small high density lipoproteins (HDL) particles comparable to human HDL3. J Biol Chem 1989;264:6488-94.
160. 160. Rubin EM, Krauss RM, Spangler EA, Verstuyft JG, Clift SM. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature 1991;353:265-7.
161. 161. Duverger N, Kruth H, Emmanuel F, Caillaud JM, Viglietta C, Castro G. Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein A-I transgenic rabbits. Circulation 1996;94:713-7.
162. 162. Plump AS, Scott CJ, Breslow JL. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mice. Proc Natl Acad Sci USA 1994;91:9607-11.
163. 163. Paszty C, Maeda N, Verstuyft J, Rubin EM. Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. J Clin Invest 1994;94:899-903.
164. 164. Liu AC, Lawn RM, Verstuyft JG, Rubin EM. Human apolipoprotein A-I prevents atherosclerosis associated with apolipoprotein (a) in transgenic mice. J Lipid Res 1994;35:2263-7.
165. 165. Kopfler WP, Willard M, Betz T, Willard JE, Gerard RD, Meidell RS. Adenovirus-mediated transfer of a gene encoding human apolipoprotein A-I into normal mice increases circulating high-density lipoprotein cholesterol. Circulation 1994;90:1319-27.
166. 166. Tsukamoto K, Hiester KG, Smith P, Usher DC, Glick JM, Rader DJ. Comparison of human apoA-I expression in mouse models of atherosclerosis after gene transfer using second generation adenovirus. J Lipid Res 1997;38:1869-76.
167. 167. Benoit P, Emmanuel F, Caillaud JM, Bassinet L, Castro G, Gallix P, et al. Somatic gene transfer of human apoA-I inhibits atherosclerosis progression in mouse models. Circulation 1999;99:105-10.
168. 168. Seguret-Mace S, Mahieu ML, Castro G, Luc G, Fruchart JC, Rubin E, et al. Potential gene therapy for lecithin-cholesterol acyltransferase (LCAT)-deficient and hypoαlipoproteinemic patients with adenovirus-mediated transfer of human LCAT gene. Circulation 1996;94:2177-84.
169. 169. Peterson J, Bengtsson-Olivecrona G, Olivecrona T. Mouse preheparin plasma contains high levels of hepatic lipase with low affinity for heparin. Biochim Biophys Acta 1986;878:65-70.
170. 170. Breckenridge WC, Little JA, Alaupovic P, Wang CS, Kuksis A, Kakis G, et al. Lipoprotein abnormalities associated with a familial deficiency of hepatic lipase. Atherosclerosis 1982;45:161-79.
171. 171. Breslow JL. Familial disorders of high-density lipoprotein metabolism. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular bases of inherited disease (vol II). New York: McGraw-Hill; 1995. p. 2031-52.
172. 172. Busch SJ, Barnhart RL, Martin GA, Fitzgerald MC, Yates MT, Mao SJT, et al. Human hepatic triglyceride lipase expression reduces high density lipoprotein and aortic cholesterol in cholesterol-fed transgenic mice. J Biol Chem 1994;269:16376-82.
173. 173. Applebaum-Bowden D, Kobayashi J, Kashyap VS, Brown D, Berard A, Meyn S, et al. Hepatic lipase gene therapy in hepatic-lipase-deficient mice. J Clin Invest 1996;97:799-805.
174. 174. Ruuskanen O, Meurman O, Akusjarvi G. Adenoviruses. In: Richman DD, Whitley RJ, Hayden FG, editors. Clinical virology. New York: Churchill Livingstone; 1997. p. 525-47.
175. 175. Graham FL, Smiley J, Russell WC, Nairn R. Characteristics of a human cell line transformed by human adenovirus type 5. J Gen Virol 1977;36:59-72.
176. 176. Hitt M, Bett AJ, Addison CL, Prevec L, Graham FL, Techniques for human adenovirus vector construction and characterization. Methods Mol Genet 1995;7:13-30.
177. 177. McGrory WJ, Bautista DS, Graham FL. A simple technique for the rescue of early region 1 mutations into infectious human adenovirus type 5. Virology 1988;163:614-7.
178. 178. Yang Y, Jooss KU, Su Q. Ertl HCJ, Wilson JM. Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Ther 1996;3:137-44.
179. 179. Tripathy SK, Black HB, Goldwasser E, Leiden JM. Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nat Med 1996;2:545-50.
180. 180. Michou AI, Santoro L, Christ M, Julliard V, Pavirani A, Mehtali M. Adenovirus-mediated gene transfer: influence of transgene, mouse strain and type of immune response on persistence of transgene expression. Gene Ther 1997;4:473-82.
181. 181. Engelhardt JF, Ye X, Doranz B, Wilson JM. Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc Natl Acad Sci USA 1994;91:6196-200.
182. 182. Yang Y, Nunes FA, Berenesi K, Gonezol E, Engelhardt JF, Wilson JM. Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nat Genet 1994;7:362-9.
183. 183. Engelhardt JF, Litzky L, Wilson JM. Prolonged transgene expression in cotton rat lung with recombinant adenoviruses defective in E2a. Hum Gene Ther 1994;5:1217-29.
184. 184. Raper SE, Haskal ZJ, Ye X, Pugh C, Furth EE, Gao GP, et al. Selective gene transfer into the liver of non-human primates with E1-deleted, E2A-defective, or E1-E4 deleted recombinant adenoviruses. Hum Gene Ther 1998;9:671-9.
185. 185. Gao GP, Yang Y, Wilson JM. Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy. J Virol 1996;70:8934-43.
186. 186. Raper SE, Wilson JM, Yudkoff M, Robinson MB, Batshaw ML. Developing adenoviral-mediated in vivo gene transfer for ornithine transcarbamylase deficiency. J Inherit Metab Dis 1998;21(suppl 1):119-37.
187. 187. Batshaw M. Phase 1 trial of adenoviral gene therapy in ornithine transcarbamylase deficiency. Presented at the Gene Therapy Symposium, sponsored by the National Gene Vector Laboratories and the National Institutes of Health. Washington DC, May 1998.
188. 188. Mitani K, Graham FL, Caskey CT, Kochanek S. Rescue, propagation, and partial purification of a helper virus-dependent adenovirus vector. Proc Natl Acad Sci USA 1995;92:3854-8.
189. 189. Parks RJ, Chen L, Anton M, Sankar U, Rudnicki MA, Graham FL. A helper-dependent adenovirus system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci USA 1996;93: 13565-70.
190. 190. Schiedner G, Morral N, Parks RJ, Wu Y, Koopmans S, Langston C, et al. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat Genet 1998;18: 180-3.
191. 191. Morsy MA, Gu MC, Motzel S, Zhao J, Lin J, Allen H, et al. An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene. Proc Natl Acad Sci USA 1998;95:7866-71.